A recent study highlights a possible role for vitamin C in managing precancerous blood disorders. The work centers on TET enzymes, cellular proteins that help decide which genes are turned on or off. When these enzymes underperform, the risk of certain blood cancers rises, making them an attractive target for intervention.
Researchers tested whether vitamin C supplements could influence this pathway. The findings suggest that vitamin C boosts TET enzyme activity, which may help restore normal gene regulation and slow or prevent progression. People with precancerous conditions who took vitamin C showed better outcomes compared to those who did not, according to the report.
The study adds to a growing body of evidence that inexpensive, widely available nutrients can affect epigenetic mechanisms. However, the source does not provide details on dosage, duration, or how large the benefit was. More rigorous trials would be needed before vitamin C could be recommended as a standard therapy for these disorders.